Canada Markets close in 1 hr 26 mins
  • S&P/TSX

    21,292.53
    +76.38 (+0.36%)
     
  • S&P 500

    4,571.90
    +27.00 (+0.59%)
     
  • DOW

    35,760.92
    +83.90 (+0.24%)
     
  • CAD/USD

    0.8075
    -0.0016 (-0.2019%)
     
  • BTC-CAD

    78,122.36
    +3,479.23 (+4.66%)
     
  • CMC Crypto 200

    1,509.18
    +1,266.50 (+521.88%)
     
  • GOLD FUTURES

    1,809.30
    +13.00 (+0.72%)
     
  • RUSSELL 2000

    2,313.54
    +22.27 (+0.97%)
     
  • 10-Yr Bond

    1.6340
    -0.0210 (-1.27%)
     
  • NASDAQ

    15,254.70
    +164.50 (+1.09%)
     
  • VOLATILITY

    15.24
    -0.19 (-1.23%)
     
  • FTSE

    7,222.82
    +18.27 (+0.25%)
     
  • NIKKEI 225

    28,600.41
    -204.44 (-0.71%)
     
  • CAD/EUR

    0.6948
    +0.0006 (+0.09%)
     

Europe Smoking Cessation Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

·2 min read

DUBLIN, September 17, 2021--(BUSINESS WIRE)--The "Europe Smoking Cessation Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Europe Smoking Cessation Market and Competitive Landscape - 2021, provides comprehensive insights into Smoking Cessation pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares. This research analyzes and forecasts Smoking Cessation market size and drug sales. It also provides insights into Smoking Cessation epidemiology and late-stage pipeline.

This research covers the following - Smoking Cessation treatment options, Smoking Cessation late-stage clinical trials pipeline, Smoking Cessation prevalence by countries, Smoking Cessation market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries. The research scope includes the countries Germany, France, Italy, Spain, UK, Europe (EU5 Countries).

Research Scope:

  • Countries: Germany, France, Italy, Spain, UK, Europe

  • Smoking Cessation pipeline: Find out drugs in clinical trials for the treatment of Smoking Cessation by development phase 3, phase 2, by pharmacological class and company

  • Smoking Cessation epidemiology: Find out the number of patients diagnosed (prevalence) with Smoking Cessation by countries

  • Smoking Cessation drugs: Identify key drugs marketed and prescribed for Smoking Cessation in the US, including trade name, molecule name, and company

  • Smoking Cessation drugs sales: Find out the sales value for Smoking Cessation drugs by countries

  • Smoking Cessation market valuations: Find out the market size for Smoking Cessation drugs in 2020 by countries. Find out how the market advanced from 2018 and forecast to 2026

  • Smoking Cessation drugs market share: Find out the market shares for key drugs by countries

Benefits of this Research:

  • Evaluate commercial market opportunities for Smoking Cessation drugs

  • Synthesize insights for business development & licensing

  • Track market size, competitor drug sales, market shares in Smoking Cessation market

  • Develop in-depth knowledge of competition and markets

  • Analyze Smoking Cessation drug sales data to update your brand planning trackers

  • Develop tactics and strategies to take advantage of opportunities in the market

  • Track Market Events and Trends and analyze key events in Smoking Cessation market

  • Develop forecast models, healthcare frameworks, or economic models

  • Answer key business questions; supports decision making in R&D to long term marketing strategies

For more information about this report visit https://www.researchandmarkets.com/r/ylh1zm

View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005355/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting